Stoke Therapeutics (STOK) Enterprise Value (2018 - 2026)

Stoke Therapeutics' Enterprise Value history runs 9 years deep, the most recent figure standing at -$343.5 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 3.86% year-over-year to -$343.5 million in Q1 2026; TTM through Mar 2026 was -$343.5 million, a 3.86% increase from a year earlier, with the FY2025 full-year figure at -$284.7 million, down 31.25% from the prior year.
• Enterprise Value fell to -$343.5 million in Q1 2026 per STOK's latest filing, from -$284.7 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$150.1 million in Q3 2024 and bottomed at -$357.3 million in Q1 2025.
• The 5-year median for Enterprise Value is -$247.7 million (2025), against an average of -$245.4 million.
• Across the five-year window, Enterprise Value soared 30.1% in 2024 and sank 100.09% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$229.6 million in 2022, then gained by 12.28% to -$201.4 million in 2023, then retreated by 7.7% to -$216.9 million in 2024, then tumbled by 31.25% to -$284.7 million in 2025, then slipped by 20.68% to -$343.5 million in 2026.
• Per Business Quant, the three latest STOK Enterprise Value figures stand at -$343.5 million (Q1 2026), -$284.7 million (Q4 2025), and -$248.3 million (Q3 2025).